Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

The emergence of neuroepidemiology, neurovirology and neuroimmunology: the legacies of John F. Kurtzke and Richard 'Dick' T. Johnson.

Kildebeck EJ, Narayan R, Nath A, Weiner H, Beh S, Calabresi PA, Steinman L, Major EO, Frohman TC, Frohman EM.

J Neurol. 2017 Apr;264(4):817-828. doi: 10.1007/s00415-016-8293-y. Epub 2016 Oct 12. No abstract available.

PMID:
27734166
2.

A decade of natalizumab and PML: Has there been a tacit transfer of risk acceptance?

Clifford DB, Yousry TA, Major EO.

Mult Scler. 2017 Jun;23(7):934-936. doi: 10.1177/1352458516670735. Epub 2016 Sep 27.

PMID:
27679459
3.

JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7.

Soleimani-Meigooni DN, Schwetye KE, Angeles MR, Ryschkewitsch CF, Major EO, Dang X, Koralnik IJ, Schmidt RE, Clifford DB, Kuhlmann FM, Bucelli RC.

J Neurovirol. 2017 Feb;23(1):141-146. doi: 10.1007/s13365-016-0465-0. Epub 2016 Jul 15.

4.

BK virus encephalopathy and sclerosing vasculopathy in a patient with hypohidrotic ectodermal dysplasia and immunodeficiency.

Darbinyan A, Major EO, Morgello S, Holland S, Ryschkewitsch C, Monaco MC, Naidich TP, Bederson J, Malaczynska J, Ye F, Gordon R, Cunningham-Rundles C, Fowkes M, Tsankova NM.

Acta Neuropathol Commun. 2016 Jul 13;4(1):73. doi: 10.1186/s40478-016-0342-3.

5.

A link between long-term natalizumab dosing in MS and PML: Putting the puzzle together.

Major EO, Nath A.

Neurol Neuroimmunol Neuroinflamm. 2016 Apr 29;3(3):e235. doi: 10.1212/NXI.0000000000000235. eCollection 2016 Jun. No abstract available.

6.

p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration.

Turnquist C, Horikawa I, Foran E, Major EO, Vojtesek B, Lane DP, Lu X, Harris BT, Harris CC.

Cell Death Differ. 2016 Sep 1;23(9):1515-28. doi: 10.1038/cdd.2016.37. Epub 2016 Apr 22.

7.

Progressive Multifocal Leukoencephalopathy in Primary Immune Deficiencies: Stat1 Gain of Function and Review of the Literature.

Zerbe CS, Marciano BE, Katial RK, Santos CB, Adamo N, Hsu AP, Hanks ME, Darnell DN, Quezado MM, Frein C, Barnhart LA, Anderson VL, Uzel G, Freeman AF, Lisco A, Nath A, Major EO, Sampaio EP, Holland SM.

Clin Infect Dis. 2016 Apr 15;62(8):986-94. doi: 10.1093/cid/civ1220. Epub 2016 Jan 6. Review.

8.

2nd International Conference on Progressive Multifocal Leukoencephalopathy (PML) 2015: JCV virology, progressive multifocal leukoencephalopathy pathogenesis, diagnosis and risk stratification, and new approaches to prevention and treatment.

Patera AC, Butler SL, Cinque P, Clifford DB, Elston R, Garcea RL, Major EO, Pavlovic D, Peterson IS, Ryan AM, Tyler KL, Weber T; PML Consortium.

J Neurovirol. 2015 Dec;21(6):702-5. doi: 10.1007/s13365-015-0392-5. No abstract available.

PMID:
26501778
9.

Cell-to-cell contact facilitates HIV transmission from lymphocytes to astrocytes via CXCR4.

Li GH, Anderson C, Jaeger L, Do T, Major EO, Nath A.

AIDS. 2015 Apr 24;29(7):755-66. doi: 10.1097/QAD.0000000000000605.

10.
11.

Direct induction of human neural stem cells from peripheral blood hematopoietic progenitor cells.

Wang T, Choi E, Monaco MC, Major EO, Medynets M, Nath A.

J Vis Exp. 2015 Jan 28;(95):52298. doi: 10.3791/52298.

12.

JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route.

Van Loy T, Thys K, Ryschkewitsch C, Lagatie O, Monaco MC, Major EO, Tritsmans L, Stuyver LJ.

J Virol. 2015 Jan 15;89(2):1340-7. doi: 10.1128/JVI.02565-14. Epub 2014 Nov 12.

13.

Contamination of SVG p12 cells with BK polyomavirus occurred after deposit in the American Type Culture Collection.

Ferenczy MW, Major EO.

J Virol. 2014 Nov;88(21):12928-9. doi: 10.1128/JVI.01600-14. No abstract available.

14.

Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis--reply.

Frohman EM, Douek D, Major EO.

JAMA Neurol. 2014 Sep;71(9):1192-3. doi: 10.1001/jamaneurol.2014.1858. No abstract available.

PMID:
25200546
15.

JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.

Frohman EM, Monaco MC, Remington G, Ryschkewitsch C, Jensen PN, Johnson K, Perkins M, Liebner J, Greenberg B, Monson N, Frohman TC, Douek D, Major EO.

JAMA Neurol. 2014 May;71(5):596-602. doi: 10.1001/jamaneurol.2014.63.

PMID:
24664166
16.

Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis.

Stoppe M, Thomä E, Liebert UG, Major EO, Hoffmann KT, Claßen J, Then Bergh F.

J Neurol. 2014 May;261(5):1021-4. doi: 10.1007/s00415-014-7311-1. Epub 2014 Mar 18. No abstract available.

PMID:
24638202
17.

Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy.

Marshall LJ, Ferenczy MW, Daley EL, Jensen PN, Ryschkewitsch CF, Major EO.

J Virol. 2014 May;88(9):5177-83. doi: 10.1128/JVI.03221-13. Epub 2014 Feb 19.

18.

Two demyelinating diseases in the brain of a single patient, PML and MS: how to minimize 'one' while treating the 'other'.

Major EO, Douek DC, Frohman EM, Walsh DR.

Expert Rev Clin Immunol. 2013 Oct;9(10):887-90. doi: 10.1586/1744666X.2013.841559. No abstract available.

PMID:
24128152
19.

More on JC viremia in natalizumab-treated patients with multiple sclerosis.

Major EO, Frohman E, Douek D.

N Engl J Med. 2013 Sep 26;369(13):1280. doi: 10.1056/NEJMc1308784. No abstract available.

20.

Clonal immortalized human glial cell lines support varying levels of JC virus infection due to differences in cellular gene expression.

Ferenczy MW, Johnson KR, Steinberg SM, Marshall LJ, Monaco MC, Beschloss AM, Jensen PN, Major EO.

J Neuroimmune Pharmacol. 2013 Dec;8(5):1303-19. doi: 10.1007/s11481-013-9499-8. Epub 2013 Sep 20.

PMID:
24052414
21.

Risk factors for rare diseases can be risky to define: PML and natalizumab.

Major EO, Douek DC.

Neurology. 2013 Sep 3;81(10):858-9. doi: 10.1212/WNL.0b013e3182a352a6. Epub 2013 Aug 7. No abstract available.

PMID:
23925759
22.

JC viremia in natalizumab-treated patients with multiple sclerosis.

Major EO, Frohman E, Douek D.

N Engl J Med. 2013 Jun 6;368(23):2240-1. doi: 10.1056/NEJMc1214233. No abstract available.

23.

Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants.

Ryschkewitsch CF, Jensen PN, Major EO.

J Clin Virol. 2013 Jul;57(3):243-8. doi: 10.1016/j.jcv.2013.03.009. Epub 2013 Apr 23.

24.

PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, Bartt R, Major EO, Nath A.

Neurology. 2013 Apr 9;80(15):1430-8. doi: 10.1212/WNL.0b013e31828c2fa1. Review.

25.

Differentiation of human fetal multipotential neural progenitor cells to astrocytes reveals susceptibility factors for JC virus.

Ferenczy MW, Johnson KR, Marshall LJ, Monaco MC, Major EO.

J Virol. 2013 Jun;87(11):6221-31. doi: 10.1128/JVI.00396-13. Epub 2013 Mar 27.

26.

Progressive multifocal leukoencephalopathy caused by BK virus?

Brew BJ, McLean CA, Major EO.

Med J Aust. 2013 Mar 4;198(4):179-80. No abstract available.

PMID:
23451948
27.

Progenitor-derived oligodendrocyte culture system from human fetal brain.

Monaco MC, Maric D, Bandeian A, Leibovitch E, Yang W, Major EO.

J Vis Exp. 2012 Dec 20;(70). pii: 4274. doi: 10.3791/4274.

28.
29.

Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.

Perkins MR, Ryschkewitsch C, Liebner JC, Monaco MC, Himelfarb D, Ireland S, Roque A, Edward HL, Jensen PN, Remington G, Abraham T, Abraham J, Greenberg B, Kaufman C, LaGanke C, Monson NL, Xu X, Frohman E, Major EO, Douek DC.

PLoS Pathog. 2012;8(11):e1003014. doi: 10.1371/journal.ppat.1003014. Epub 2012 Nov 8.

30.

Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.

Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, Major EO.

Clin Microbiol Rev. 2012 Jul;25(3):471-506. doi: 10.1128/CMR.05031-11. Review.

31.

Neurological infections: risks of globalisation and new drugs.

Major EO, Nath A.

Lancet Neurol. 2012 Jan;11(1):14-5. doi: 10.1016/S1474-4422(11)70279-4. No abstract available.

PMID:
22172615
32.

Individuals infected with JC polyomavirus do not present detectable JC virus DNA in oropharyngeal fluids.

Matos A, Duque V, Luxo C, Meliço-Silvestre A, Major EO.

J Gen Virol. 2012 Apr;93(Pt 4):692-7. doi: 10.1099/vir.0.036798-0. Epub 2011 Dec 7.

PMID:
22158878
33.

The link between VLA-4 and JC virus reactivation.

Monaco MC, Major EO.

Expert Rev Clin Immunol. 2012 Jan;8(1):63-72. doi: 10.1586/eci.11.85. Review.

PMID:
22149341
34.

History and current concepts in the pathogenesis of PML.

Major EO.

Cleve Clin J Med. 2011 Nov;78 Suppl 2:S3-7. doi: 10.3949/ccjm.78.s2.02.

PMID:
22123932
35.

Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.

Kuhle J, Gosert R, Bühler R, Derfuss T, Sutter R, Yaldizli O, Radue EW, Ryschkewitsch C, Major EO, Kappos L, Frank S, Hirsch HH.

Neurology. 2011 Dec 6;77(23):2010-6. doi: 10.1212/WNL.0b013e31823b9b27. Epub 2011 Nov 9.

36.

JC virus promoter/enhancers contain TATA box-associated Spi-B-binding sites that support early viral gene expression in primary astrocytes.

Marshall LJ, Moore LD, Mirsky MM, Major EO.

J Gen Virol. 2012 Mar;93(Pt 3):651-61. doi: 10.1099/vir.0.035832-0. Epub 2011 Nov 9.

37.

Susceptibility of human primary neuronal cells to xenotropic murine leukemia virus-related (XMRV) virus infection.

Ravichandran V, Major EO, Ibe C, Monaco MC, Girisetty MK, Hewlett IK.

Virol J. 2011 Sep 20;8:443. doi: 10.1186/1743-422X-8-443.

38.

Immune reconstitution inflammatory syndrome in natalizumab-associated PML.

Tan IL, McArthur JC, Clifford DB, Major EO, Nath A.

Neurology. 2011 Sep 13;77(11):1061-7. doi: 10.1212/WNL.0b013e31822e55e7. Epub 2011 Aug 10.

39.

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.

Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O'Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radü EW, Sørensen PS, King J.

Lancet Neurol. 2011 Aug;10(8):745-58. doi: 10.1016/S1474-4422(11)70149-1. Review.

PMID:
21777829
40.

Taxonomical developments in the family Polyomaviridae.

Johne R, Buck CB, Allander T, Atwood WJ, Garcea RL, Imperiale MJ, Major EO, Ramqvist T, Norkin LC.

Arch Virol. 2011 Sep;156(9):1627-34. doi: 10.1007/s00705-011-1008-x. Epub 2011 May 12.

41.

IFN-gamma mediates enhancement of HIV replication in astrocytes by inducing an antagonist of the beta-catenin pathway (DKK1) in a STAT 3-dependent manner.

Li W, Henderson LJ, Major EO, Al-Harthi L.

J Immunol. 2011 Jun 15;186(12):6771-8. doi: 10.4049/jimmunol.1100099. Epub 2011 May 11.

42.

Inhibitory interactions between BK and JC virus among kidney transplant recipients.

Cheng XS, Bohl DL, Storch GA, Ryschkewitsch C, Gaudreault-Keener M, Major EO, Randhawa P, Hardinger KL, Brennan DC.

J Am Soc Nephrol. 2011 May;22(5):825-31. doi: 10.1681/ASN.2010080877. Epub 2011 Apr 21.

43.

CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes.

Gosert R, Rinaldo CH, Wernli M, Major EO, Hirsch HH.

Antimicrob Agents Chemother. 2011 May;55(5):2129-36. doi: 10.1128/AAC.00046-11. Epub 2011 Mar 14.

44.

Reply: To PMID 21246607.

Major EO, Ryschkewitsch CF, Jensen PN, Monaco MC.

Ann Neurol. 2011 Feb;69(2):430-1. doi: 10.1002/ana.22364. No abstract available.

45.

Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity.

Marshall LJ, Dunham L, Major EO.

J Gen Virol. 2010 Dec;91(Pt 12):3042-52. doi: 10.1099/vir.0.023184-0. Epub 2010 Sep 8.

46.

Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures.

Jiang ZG, Cohen J, Marshall LJ, Major EO.

Antimicrob Agents Chemother. 2010 Nov;54(11):4723-32. doi: 10.1128/AAC.00837-10. Epub 2010 Sep 7.

47.

JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab.

Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO.

Ann Neurol. 2010 Sep;68(3):384-91. doi: 10.1002/ana.22137.

48.
49.

Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy.

Marshall LJ, Major EO.

J Neuroimmune Pharmacol. 2010 Sep;5(3):404-17. doi: 10.1007/s11481-010-9203-1. Epub 2010 Apr 17. Review.

50.

Differences in NMDA receptor expression during human development determine the response of neurons to HIV-tat-mediated neurotoxicity.

Eugenin EA, King JE, Hazleton JE, Major EO, Bennett MV, Zukin RS, Berman JW.

Neurotox Res. 2011 Jan;19(1):138-48. doi: 10.1007/s12640-010-9150-x. Epub 2010 Jan 22.

Supplemental Content

Loading ...
Support Center